Cheong Sxe Chang, So Shing Lok, Lal Alexander, Coveliers-Munzi Jan
School of Medicine and Population Health, University of Sheffield, Sheffield, United Kingdom.
School of Health and Medical Sciences, St. George's, University of London, London, United Kingdom.
Front Pediatr. 2025 Aug 12;13:1581578. doi: 10.3389/fped.2025.1581578. eCollection 2025.
Acute kidney injury (AKI) frequently complicates pediatric cardiac surgery with high incidence and outcomes. Conventional markers (KDIGO criteria) often fall short for pediatric patients undergoing cardiac surgery. Emerging machine learning models offer improved early detection and risk stratification. This review evaluates ML models' feasibility, performance, and generalizability in predicting pediatric AKI.
This systematic review adheres to PRISMA-DTA guidelines. Search was conducted on PubMed and Medline (Ovid/Embase) on March 24, 2024, using PICOTS-based keywords. Titles, abstracts, and full texts were screened for eligibility. Data on study characteristics and best-performing ML models' AUROC, sensitivity, and specificity were extracted. PROBAST evaluated risk of bias and applicability comprehensively. A narrative synthesis approach was employed to summarize findings due to heterogeneity in study designs and outcome measures.
Nine unique studies were identified and included, eight focused on post-cardiac surgery, and one on both PICU admissions and post-cardiac surgery patients. PROBAST demonstrated high risk of bias and low applicability amongst the studies, with notably limited external validation.
While ML models predicting AKI in post-cardiac surgery pediatric patients show promising discriminatory ability with prediction lead times up to two days, outperforming traditional biomarkers and KDIGO criteria, findings must be interpreted cautiously. High risk of bias across studies, particularly lack of external validation, substantially limits evidence strength and clinical applicability. Variations in study design, patient populations, and outcome definitions complicate direct comparisons. Robust external validation through multicenter cohorts using standardized guidelines is essential before clinical implementation. Current evidence, though promising, is insufficient for widespread adoption without addressing these methodological limitations.
PROSPERO CRD420250604781.
急性肾损伤(AKI)常使小儿心脏手术复杂化,发病率高且预后不佳。传统标志物(KDIGO标准)对于接受心脏手术的小儿患者往往并不适用。新兴的机器学习模型可改善早期检测和风险分层。本综述评估了机器学习模型在预测小儿急性肾损伤方面的可行性、性能和通用性。
本系统综述遵循PRISMA-DTA指南。于2024年3月24日在PubMed和Medline(Ovid/Embase)上进行检索,使用基于PICOTS的关键词。对标题、摘要和全文进行筛选以确定是否符合纳入标准。提取有关研究特征以及表现最佳的机器学习模型的受试者工作特征曲线下面积(AUROC)、敏感性和特异性的数据。PROBAST全面评估了偏倚风险和适用性。由于研究设计和结局指标存在异质性,采用叙述性综合方法总结研究结果。
共识别并纳入了9项独特的研究,其中8项聚焦于心脏手术后,1项同时涉及儿科重症监护病房(PICU)入院患者和心脏手术后患者。PROBAST表明这些研究存在高偏倚风险和低适用性,外部验证明显有限。
虽然预测心脏手术后小儿患者急性肾损伤的机器学习模型显示出有前景的鉴别能力,预测提前期可达两天,优于传统生物标志物和KDIGO标准,但对研究结果的解读必须谨慎。各研究存在高偏倚风险,尤其是缺乏外部验证,这极大地限制了证据强度和临床适用性。研究设计、患者群体和结局定义的差异使直接比较变得复杂。在临床应用之前,通过多中心队列使用标准化指南进行强有力的外部验证至关重要。目前的证据虽然有前景,但在未解决这些方法学局限性的情况下,不足以广泛应用。
PROSPERO CRD420250604781